RU2293727C2 - Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью и содержащие их фармацевтические композиции - Google Patents

Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью и содержащие их фармацевтические композиции Download PDF

Info

Publication number
RU2293727C2
RU2293727C2 RU2004100302/04A RU2004100302A RU2293727C2 RU 2293727 C2 RU2293727 C2 RU 2293727C2 RU 2004100302/04 A RU2004100302/04 A RU 2004100302/04A RU 2004100302 A RU2004100302 A RU 2004100302A RU 2293727 C2 RU2293727 C2 RU 2293727C2
Authority
RU
Russia
Prior art keywords
carbon atoms
heteroaryl
alkyl
phenyl
group
Prior art date
Application number
RU2004100302/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2004100302A (ru
Inventor
Йоахим БРЕНДЕЛЬ (DE)
Йоахим Брендель
Томас БЕМЕ (DE)
Томас Беме
Штефан ПОЙКЕРТ (DE)
Штефан Пойкерт
Хайнц-Вернер КЛЕЕМАНН (DE)
Хайнц-Вернер КЛЕЕМАНН
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Publication of RU2004100302A publication Critical patent/RU2004100302A/ru
Application granted granted Critical
Publication of RU2293727C2 publication Critical patent/RU2293727C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2004100302/04A 2001-06-12 2002-05-31 Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью и содержащие их фармацевтические композиции RU2293727C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331.8 2001-06-12

Publications (2)

Publication Number Publication Date
RU2004100302A RU2004100302A (ru) 2005-04-10
RU2293727C2 true RU2293727C2 (ru) 2007-02-20

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004100302/04A RU2293727C2 (ru) 2001-06-12 2002-05-31 Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью и содержащие их фармацевтические композиции

Country Status (40)

Country Link
US (2) US6903216B2 (https=)
EP (1) EP1399423B9 (https=)
JP (1) JP4422477B2 (https=)
KR (1) KR100863924B1 (https=)
CN (1) CN1247544C (https=)
AR (1) AR036045A1 (https=)
AT (1) ATE378318T1 (https=)
AU (1) AU2002316939B2 (https=)
BG (1) BG108415A (https=)
BR (1) BR0210374A (https=)
CA (1) CA2450076C (https=)
CO (1) CO5540283A2 (https=)
CR (1) CR7140A (https=)
CY (1) CY1107427T1 (https=)
CZ (1) CZ20033361A3 (https=)
DE (2) DE10128331A1 (https=)
DK (1) DK1399423T3 (https=)
EC (1) ECSP034883A (https=)
EE (1) EE05196B1 (https=)
ES (1) ES2295360T3 (https=)
HR (1) HRP20031028A2 (https=)
HU (1) HUP0400159A3 (https=)
IL (2) IL159247A0 (https=)
MA (1) MA27037A1 (https=)
MX (1) MXPA03010875A (https=)
MY (1) MY138341A (https=)
NO (1) NO20035450D0 (https=)
NZ (1) NZ530081A (https=)
OA (1) OA12631A (https=)
PE (1) PE20021066A1 (https=)
PL (1) PL364371A1 (https=)
PT (1) PT1399423E (https=)
RS (1) RS97703A (https=)
RU (1) RU2293727C2 (https=)
SK (1) SK15222003A3 (https=)
TN (1) TNSN03134A1 (https=)
TW (1) TWI304400B (https=)
UA (1) UA75412C2 (https=)
WO (1) WO2002100825A2 (https=)
ZA (1) ZA200308520B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
BR0309522A (pt) * 2002-04-26 2005-02-09 Ishihara Sangyo Kaisha Compostos piridina ou sais destes e herbicidas contendo os mesmos
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
SI1651621T1 (sl) 2003-08-08 2008-12-31 Janssen Pharmaceutica Nv 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
CA2581426A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
RU2436577C2 (ru) * 2006-04-27 2011-12-20 Санофи-Авентис Дойчланд Гмбх Ингибиторы ионных task-1 и task-3 каналов
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CA2765611A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
RU2561132C2 (ru) * 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
RU2414893C1 (ru) * 2009-11-11 2011-03-27 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Четвертичное аммониевое производное новокаина, обладающее противоаритмической активностью, и способ его получения
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (https=) 2011-07-01 2018-04-28
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
WO2019031472A1 (ja) * 2017-08-07 2019-02-14 国立大学法人広島大学 新規アントラニル酸系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150356A (en) * 1998-09-01 2000-11-21 Bristol-Myers Squibb Company Potassium channel inhibitors and method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686625B1 (en) 1993-12-27 1999-05-26 Eisai Co., Ltd. Anthranilic acid derivative
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
CN1332943C (zh) * 1998-07-08 2007-08-22 萨诺费-阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n-芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
MXPA02000123A (es) * 1999-06-24 2002-07-02 Smithkline Beecham Corp Antagonistas de receptor depurador de macrofago.
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150356A (en) * 1998-09-01 2000-11-21 Bristol-Myers Squibb Company Potassium channel inhibitors and method

Also Published As

Publication number Publication date
EP1399423B9 (de) 2008-02-27
PL364371A1 (en) 2004-12-13
JP4422477B2 (ja) 2010-02-24
BG108415A (en) 2004-07-30
DE10128331A1 (de) 2002-12-19
CN1529695A (zh) 2004-09-15
WO2002100825A2 (de) 2002-12-19
SK15222003A3 (sk) 2004-06-08
US7235664B2 (en) 2007-06-26
CY1107427T1 (el) 2012-12-19
HUP0400159A3 (en) 2008-10-28
CR7140A (es) 2004-04-15
NZ530081A (en) 2005-07-29
MXPA03010875A (es) 2004-02-17
CO5540283A2 (es) 2005-07-29
OA12631A (fr) 2006-06-14
ZA200308520B (en) 2004-09-06
IL159247A (en) 2010-06-16
WO2002100825A3 (de) 2003-12-11
DK1399423T3 (da) 2008-03-17
NO20035450D0 (no) 2003-12-08
CA2450076C (en) 2010-11-30
UA75412C2 (en) 2006-04-17
CZ20033361A3 (cs) 2004-05-12
ES2295360T3 (es) 2008-04-16
US20050137200A1 (en) 2005-06-23
EE05196B1 (et) 2009-08-17
DE50211213D1 (de) 2007-12-27
KR100863924B1 (ko) 2008-10-17
EP1399423B1 (de) 2007-11-14
ATE378318T1 (de) 2007-11-15
CA2450076A1 (en) 2002-12-19
HK1065316A1 (en) 2005-02-18
ECSP034883A (es) 2004-01-28
US6903216B2 (en) 2005-06-07
EP1399423A2 (de) 2004-03-24
KR20040030668A (ko) 2004-04-09
BR0210374A (pt) 2004-07-13
PE20021066A1 (es) 2003-01-21
HUP0400159A2 (hu) 2004-07-28
PT1399423E (pt) 2008-02-07
IL159247A0 (en) 2004-06-01
TNSN03134A1 (en) 2005-12-23
CN1247544C (zh) 2006-03-29
EE200300558A (et) 2004-02-16
RU2004100302A (ru) 2005-04-10
JP2004533464A (ja) 2004-11-04
AR036045A1 (es) 2004-08-04
HRP20031028A2 (en) 2005-10-31
MY138341A (en) 2009-05-29
US20030114499A1 (en) 2003-06-19
RS97703A (sr) 2006-12-15
TWI304400B (en) 2008-12-21
MA27037A1 (fr) 2004-12-20
AU2002316939B2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
RU2293727C2 (ru) Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью и содержащие их фармацевтические композиции
RU2283833C2 (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
ES2602615T3 (es) Agentes antibacterianos
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
PL207057B1 (pl) Orto-podstawione związki bisarylowe, zawierające azot, preparat farmaceutyczny zawierający związki biasarylowe oraz zastosowanie związków biasarylowych
CN100497314C (zh) 取代的4-苯基四氢异喹啉、其制备方法、其用作药物的用途以及含有它们的药物
WO2011145669A1 (ja) アミド誘導体
JPWO2000015603A1 (ja) ベンゼン誘導体及びその医薬用途
CA2696429A1 (en) Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
EP0326106B1 (en) Alkylene diamines
CN101602750B (zh) 萘基、(取代)芳基、哌嗪基脒类化合物
CN115093444B (zh) 一种萘磺酰胺磷酸酯类小分子化合物及其应用
CN114436945B (zh) 一种苯磺酰胺类化合物、制备方法及应用
SK17698A3 (en) Sulfonamide substituted compounds, a medicament containing same and their use
CN107056819A (zh) 一种预防和治疗心肌缺血的药物及其制备方法
CN121914087A (zh) 嘧啶类化合物及其制备方法、药物组合物和用途
JP2026067760A (ja) C3a受容体拮抗化合物及びその利用
CN114502530A (zh) 抑制组蛋白乙酰转移酶p300的新型化合物及其抗纤维化组合物
HK1064663B (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
JPWO2001016091A1 (ja) ビスシクロプロパンカルボン酸アミド化合物およびその医薬用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110601